Immutep announces final data from Part B of its TACTI-002 Phase II trial

Immutep announces positive final data from Part B of the TACTI-002 Phase II trial in 2nd line metastatic non-small cell lung cancer, NSCLC, patients refractory to anti-PD-(L)1 therapy via a Mini Oral presentation at ESMO’s European Lung Cancer Congress, ELCC, 2023. The presentation by Margarita Majem, M.D., Ph.D., Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, titled "Final data from a phase II study of eftilagimod alpha & pembrolizumab 2nd line metastatic NSCLC patients resistant to PD-1/PD-L1 inhibitors" discusses how eftilagimod alpha, a soluble LAG-3 protein, targets a subset of MHC class II molecules found on antigen-presenting cells to mediate their activation and subsequent CD8+ T cell activation/proliferation. All patients had confirmed progression after standard-of-care 1st line treatment with anti-PD-X therapy, including 67% that received anti-PD-X therapy and chemotherapy. In these PD-X refractory, 2L metastatic NSCLC patients, the chemo-free combination of efti plus pembrolizumab achieved a median Overall Survival of 9.9 months and a 39% OS rate at 21 months, which compare favorably to typical 6-9 months mOS and a 10-15% OS rate at 21 months for standard-of-care chemotherapy. Efti plus pembrolizumab had an ORR of 8.3%, a DCR of 33%, and a 6-month PFS rate of 25% in the all-comer PD-L1 patient population, with most of these PD-X refractory patients having negative or low PD-L1 expression. The ORR, PFS, and OS were more pronounced in patients with high PD-L1 expression or who were secondary resistant. For patients with greater than or equal to50% PD-L1 TPS expression, mOS was not yet reached, ORR was 33.3%, and 6-month PFS was 50%. Efti plus pembrolizumab was well tolerated without any new safety signals, and there was no treatment discontinuation due to adverse reactions.